These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 7470579)

  • 1. Changes of the blood lymphocyte population in cancer patients treated with bestatin, a new immunomodulator. A phase I study.
    Blomgren H; Strender LE; Edsmyr F
    Biomedicine; 1980 Dec; 32(4):178-85. PubMed ID: 7470579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Partial review of immunotherapeutic pharmacology in stem cell transplantation.
    Bierman PJ; Abe F; Buyukberber S; Ino K; Talmadge JE
    In Vivo; 2000; 14(1):221-36. PubMed ID: 10757081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bestatin treatment and the peripheral lymphocyte population in cancer patients.
    Blomgren H; Strender LE; Edsmyr F
    Recent Results Cancer Res; 1980; 75():133-8. PubMed ID: 7232824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunological and haematological monitoring in bladder cancer patients receiving adjuvant bestatin treatment following radiation therapy. A prospective randomized trial.
    Blomgren H; Edsmyr F; Esposti PL; Näslund I
    Biomed Pharmacother; 1984; 38(3):143-9. PubMed ID: 6383491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bestatin treatment enhances the recovery of radiation induced impairments of the immunological reactivity of the blood lymphocyte population in bladder cancer patients.
    Blomgren H; Edsmyr F; von Stedingk LV; Wasserman J
    Biomed Pharmacother; 1986; 40(2):50-4. PubMed ID: 3756312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bestatin treatment of human lymphocytes increases the frequency of sheep red blood cell-binding cells.
    Blomgren H; Wasserman J
    Cancer Lett; 1981 Feb; 11(4):303-8. PubMed ID: 7296523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of Bestatin, a new immunomodulator, on various functions of human monocytes.
    Jarstrand C; Blomgren H
    J Clin Lab Immunol; 1982 Dec; 9(3):193-8. PubMed ID: 7166751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bestatin, a new immunomodulator, augments the release of mitogenic factors from PHA-stimulated human lymphocytes.
    Blomgren H
    Biomedicine; 1981 Dec; 34(4):188-92. PubMed ID: 6979352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The immunomodulating action of bestatin in the combined therapy of bladder cancer patients].
    Neprina GS; Panteleeva ES; Vatin OE; Kariakin OB
    Urol Nefrol (Mosk); 1994; (2):34-8. PubMed ID: 8017004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Experimental and clinical studies of bestatin as an immunomodulator].
    Miwa H; Oka T; Tsurumi T; Sakae Y; Orita K
    Gan To Kagaku Ryoho; 1982 Jul; 9(6):1019-24. PubMed ID: 7184437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunomodulating properties of bestatin in cancer patients. A phase II trial.
    Mathé G; Umezawa H; Misset JL; Brienza S; Canon C; Musset M; Reizenstein P
    Biomed Pharmacother; 1986; 40(10):379-82. PubMed ID: 3495299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restoration of E-rosette formation by bestatin in patients with bladder cancer.
    Yokoyama H; Umeda T; Kobayashi K; Akaza H; Niijima T
    J Cancer Res Clin Oncol; 1980; 98(2):195-201. PubMed ID: 7217183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Phase I study of Bestatin: (I) A clinical study on determination of an optimal dose of Bestatin].
    Saito K; Miyasato H; Tajima K; Ikeda S
    Gan To Kagaku Ryoho; 1983 Feb; 10(2 Pt):211-7. PubMed ID: 6881973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Initial results of the clinical use of the immunostimulant bestatin (3-amino-2-hydroxy-4-phenylbutyryl leucine) in patients with chronic polyarthritis].
    Meske S; Vogt P; Maly FE; Seitz M; Müller W
    Z Rheumatol; 1985; 44(5):231-6. PubMed ID: 4082790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro augmentation of cytotoxic activity of peripheral blood lymphocytes and spleen cells of cancer patients by ubenimex.
    Iwahashi M; Tanimura H; Yamaue H; Tsunoda T; Tani M; Noguchi K; Mizobata S; Tamai M; Hotta T; Arii K
    Anticancer Res; 1994; 14(4A):1557-62. PubMed ID: 7979185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Determination of active T lymphocytes in the peripheral blood by the AE rosette test. Correlation of the AE and E rosette tests with lymphocyte reactivity in vitro after PHA stimulation].
    Karwowska W; Kunicka A
    Probl Med Wieku Rozwoj; 1982; 11():111-6. PubMed ID: 6983690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term effects on the immune system following local radiation therapy for breast cancer. III. Changes of spontaneous and lectin dependent cellular cytotoxicity.
    Rotstein S; Blomgren H; Petrini B; Wasserman J; Baral E
    Anticancer Res; 1986; 6(1):113-8. PubMed ID: 3513692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A new antitumor drug with immunomodulating activity, ubenimex (bestatin)].
    Tsukagoshi S
    Gan To Kagaku Ryoho; 1987 Jul; 14(7):2385-91. PubMed ID: 3496857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aminopeptidase inhibitor ubenimex (bestatin) inhibits the growth of human choriocarcinoma in nude mice through its direct cytostatic activity.
    Inoi K; Goto S; Nomura S; Isobe K; Nawa A; Okamoto T; Tomoda Y
    Anticancer Res; 1995; 15(5B):2081-7. PubMed ID: 8572606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Study on the antitumor effect of an inhibitor against cell surface enzyme (Bestatin)].
    Sonoyama T; Terata N; Matsumoto H; Nozaki A; Kimura K; Kurioka H; Hashimoto I; Tsunoda F; Kodama M
    Nihon Gan Chiryo Gakkai Shi; 1982 Aug; 17(5):1264-9. PubMed ID: 6984058
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.